Diag-Nose.io, a Seattle, WA-based respiratory healthcare firm, raised $2M in Seed funding.
The spherical was led by Breakthrough Victoria, with participation from Radar Ventures, a syndicate of physicians from Specialty Doctor Associates (SPA), biotech angel traders Carl Stubbings, Stephen Ho, and Richard Lipscombe, in addition to physicians affiliated with main U.S. hospitals. Carl Stubbings will be part of Diag-Nostril.io’s board as Chairperson.
The corporate intends to make use of the funds to develop operations and its R&D efforts.
Based in 2020 and led by CEO Eldin Rostom, Diag-Nostril.io is a biotechnology firm targeted on translating the complexities of the unified airway into precision diagnostic and drug discovery options. Its RhinoMAP™ platform combines machine studying (synthetic intelligence) with superior proteomics to allow precision-matched remedies primarily based on every affected person’s distinctive organic profile, or “endotype.”
The system leverages patented nasal liquid biopsy know-how, the ABEL Microsampler™, to gather nasal fluid samples for complete biomarker evaluation. These insights intend to information care by figuring out illness development, therapeutic responsiveness, and optimum remedy pathways.
FinSMEs
03/02/2025
